Biotech’s year in review ++

https://www.statnews.com/2025/12/18/readout-loud-podcast-biotech-venture-capital-obesity-coverage/ By Allison DeAngelis, Elaine Chen, and Adam FeuersteinDec. 18, 2025 In major effort to end gender-affirming care, Trump administration takes aim at hospitals Proposed rules threaten financial consequences for clinics providing such care to trans minors https://www.statnews.com/2025/12/18/transgender-care-hospitals-trump-cms-rules/ By Theresa Gaffney, Daniel Payne, and Chelsea CirruzzoDec. 18, 2025

NIH funding rates for early-career researchers plunged in 2025, new data show Change in how grants are paid undercut support for young scientists, an agency priority

https://www.statnews.com/2025/12/18/nih-early-career-researchers-grant-success-rate-falls/ By Anil Oza and Jonathan WosenDec. 18, 2025

Trump’s marijuana reclassification could boost research, broaden access President weighs in on debate between hard-liners and those who want more research on drug’s medical uses

https://www.statnews.com/2025/12/18/trump-reclassifies-marijuana-to-boost-research-and-access/ By Lev FacherDec. 18, 2025 Addiction Reporter

Facing federal hostility, supervised consumption site points to 1,900 overdose reversals New York officials show support for OnPoint even as Trump administration criticizes harm reduction

https://www.statnews.com/2025/12/18/on-point-nyc-drug-consumption-site-trump-defiance/ By Lev FacherDec. 18, 2025 Addiction Reporter

5 lessons for U.S. research funding from the AIDS crisis Medicine can’t wait for Washington

https://www.statnews.com/2025/12/19/aids-research-federal-funding-cuts-lessons/ By Robert B. ShpinerDec. 19, 2025 Shpiner is a clinical professor of medicine (pulmonary and critical care) at the UCLA David Geffen School of Medicine.

U.K.’s state-owned investment bank shows up in the U.S., eager to spend on biotech British Business Bank has billions to put into life sciences VC firms and startups, other key sectors

https://www.statnews.com/2025/12/19/uk-biotech-life-sciences-investment/ By Allison DeAngelisDec. 19, 2025 Biotech Startups and Venture Capital Reporter

I’m the former head of Pfizer R&D. I’m very worried about biopharma’s future The New York Times once called me ‘Dr. Optimistic.’ I’m not so optimistic now

https://www.statnews.com/2025/12/19/pharmaceutical-industry-future-rfk-jr-trump/ By John L. LaMattinaDec. 19, 2025 LaMattina is the former president of Pfizer Global R&D and is currently a senior director at PureTech Health.